|Day Low/High||182.88 / 187.15|
|52 Wk Low/High||176.36 / 242.99|
A rally in crude oil gave rise to the energy sector in a mixed day of trading.
Acquiring CTP-656 from Concert Pharmaceuticals will only cost Vertex around $250 million.
Jana Partners are placing three members on Tiffany's board.
Vertex Pharmaceuticals will be weighing future acquisitions and partnerships to broaden is focus beyond cystic fibrosis.
Vertex Pharmaceuticals provided new financial guidance for 2017 on Sunday.
The biggest annual event for biotech and pharma investors starts Monday with the kickoff of the J.P. Morgan Healthcare Conference in San Francisco.
Buy signals have not lasted more than two months, so far.
These stocks are down some 20% over the last 30 months and look ripe for a rise.
The rate of decline slowed into the base, just what chartists like to see.
There are some good buying ideas among these stocks.
It’s been a hot M&A market for biotech companies developing treatments for rare diseases.
Sector may not be as bulletproof as we thought.
Jim Cramer answers viewers' stock questions from the floor of the New York Stock Exchange.
A Picasso Painting Fetched $179 million dollars at an auction at Christie's Monday night, the most ever paid for a work of art at auction.
AbbVie is a cheap stock and worries about competition immediately hurting its rheumatoid arthritis drug Humira are overblown, said John Schroer, Portfolio Manager for the AllianzGI Health Sciences Fund.